40 results on '"Mayer, Erica L."'
Search Results
2. Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial.
- Author
-
Leonard, Saskia, Jones, Alyssa N., Newman, Lisa, Chavez-MacGregor, Mariana, Freedman, Rachel A., Mayer, Erica L., Mittendorf, Elizabeth A., King, Tari A., and Kantor, Olga
- Abstract
Purpose: Breast cancer mortality is higher in Black women than other racial groups. This difference has been partially attributed to a higher proportion of triple-negative breast cancer (TNBC). However, it is uncertain if survival disparities exist in racially diverse TNBC patients receiving similar treatments. Here, we examine racial differences in disease-related outcomes in TNBC patients treated on the E5103 clinical trial. Methods: From 2007 to 2011, 4,994 patients with stage I-III HER2-negative breast cancer were randomized to adjuvant chemotherapy with or without bevacizumab. This analysis was limited to the subset of 1,742 TNBC patients with known self-reported race. Unadjusted Kaplan-Meier curves and adjusted Cox-Proportional Hazards models were used to determine breast cancer events and survival outcomes. Results: Of the analysis population, 51 (2.9%) were Asian, 269 (15.4%) Black, and 1422 (81.6%) White. Median age was 51 years. Patient characteristics, treatment arm, and local therapies were similar across racial groups. White women were more commonly node-negative (56% vs. 49% and 44% in Asian and Black women, respectively; p < 0.01). At a median follow-up of 46 months, unadjusted Kaplan-Meier locoregional and distant recurrence, and disease-free and overall survival, did not differ significantly by race. In Cox models adjusted for patient and tumor characteristics and treatment arm, race was not associated with any disease event. Larger tumor size and nodal involvement were consistently associated with breast cancer events. Conclusion: This clinical trial population of similarly treated TNBC patients showed no racial differences in breast cancer outcomes. Disease extent, rather than race, was associated with disease events. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Association of N-terminal pro–brain natriuretic peptide with survival among US cancer survivors.
- Author
-
Cao, Chao, Yang, Lin, Nohria, Anju, Mayer, Erica L, Partridge, Ann H, and Ligibel, Jennifer A
- Subjects
BRAIN natriuretic factor ,CANCER survivors ,HEALTH & Nutrition Examination Survey ,CANCER patients - Abstract
Background N-terminal pro–brain natriuretic peptide (NT-proBNP) is a cardiac biomarker associated with the risk of heart failure and death in the general population, but it has not been explored in cancer survivors. Methods Using a US nationally representative sample of adults 20 years of age and older from the National Health and Nutrition Examination Survey from 1999 to 2004, this study compared NT-proBNP levels between adults without cancer (n = 12 574) and adult cancer survivors (n = 787). It examined the association of NT-proBNP with all-cause and cause-specific mortality among cancer survivors. Results Cancer survivors had higher NT-proBNP levels than adults without cancer (median [interquartile range] = 125.4 pg/mL [52.4-286.0] vs 43.2 pg/mL [20.3-95.0]). In particular, survivors of breast, prostate, and colorectal cancers had higher NT-proBNP levels than adults without cancer (multivariable-adjusted P < .05). In total, 471 survivors died (141 from cancer; 95 from cardiac disease) during a median follow-up period of 13.4 years (9393 person-years). Among cancer survivors, higher NT-proBNP levels were statistically associated with increased risks of all-cause death (hazard ratio [HR] = 1.31, 95% confidence interval [CI] = 1.18 to 1.46) and cardiac death (HR = 1.55, 95% CI = 1.21 to 2.00) but not with death from cancer (HR = 1.10, 95% CI = 0.92 to 1.32]). Higher NT-proBNP levels were associated with elevated overall mortality in survivors of prostate cancer (HR = 1.49, 95% CI = 1.22 to 1.81) and colorectal cancer (HR = 1.78, 95% CI = 1.00 to 3.16) (P = .169 for interaction). Nonlinear dose-response relationships were observed between NT-proBNP and mortality, with statistically significant relationships emerging above 125 pg/mL. Conclusions Cancer survivors had higher NT-proBNP levels than adults without cancer, and elevated NT-proBNP levels were associated with higher risks of all-cause and cardiac mortality in cancer survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
- Author
-
Smith, Karen L., Fengmin Zhao, Mayer, Ingrid A., Tevaarwerk, Amye J., Garcia, Sofia F., Arteaga, Carlos L., Symmans, William F., Park, Ben H., Burnette, Brian L., Makower, Della F., Block, Margaret, Morley, Kimberly A., Jani, Chirag R., Mescher, Craig, Dewani, Shabana J., Brown-Glaberman, Ursa, Flaum, Lisa E., Mayer, Erica L., Sikov, William M., and Rodler, Eve T.
- Subjects
TRIPLE-negative breast cancer ,PATIENT reported outcome measures ,PATIENT experience ,PATIENTS' attitudes ,PLATINUM - Abstract
Background: Patient-reported outcomes (PROs) are a better tool for evaluating the experiences of patients who have symptomatic, treatment-associated adverse events (AEs) compared with clinician-rated AEs. The authors present PROs assessing health-related quality of life (HRQoL) and treatment-related neurotoxicity for adjuvant capecitabine versus platinum on the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) EA1131 trial (ClinicalTrials.gov identifier NCT02445391). Methods: Participants completed the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) and the Functional Assessment of Cancer Therapy-Gynecologic Oncology Group neurotoxicity subscale (platinum arm only) at baseline, cycle 3 day 1 (C3D1), 6 months, and 15 months. Because of early termination, power was insufficient to test the hypothesis that HRQoL, as assessed by the NFBSI-16 treatment side-effect (TSE) subscale, would be better at 6 and 15 months in the capecitabine arm; all analyses were exploratory. Means were compared by using t-tests or the Wilcoxon rank-sum test, and proportions were compared by using the χ2 test. Results: Two hundred ninety-six of 330 eligible patients provided PROs. The mean NFBSI-16 TSE subscale score was lower for the platinum arm at baseline (p = .02; absolute difference, 0.6 points) and for the capecitabine arm at C3D1 (p = .04; absolute difference, 0.5 points), but it did not differ at other times. The mean change in TSE subscale scores differed between the arms from baseline to C3D1 (platinum arm, 0.15; capecitabine arm, -0.72; p = .03), but not from baseline to later time points. The mean decline in Functional Assessment of Cancer Therapy-Gynecologic Oncology Group neurotoxicity subscale scores exceeded the minimal meaningful change (1.38 points) from baseline to each subsequent time point (all p < .05). Conclusions: Despite the similar frequency of clinician-rated AEs, PROs identified greater on-treatment symptom burden with capecitabine and complemented clinician-rated AEs by characterizing patients' experiences during chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
- Author
-
Mayer, Erica L., Tayob, Nabihah, Ren, Siyang, Savoie, Jennifer J., Spigel, David R., Burris III, Howard A., Ryan, Paula D., Harris, Lyndsay N., Winer, Eric P., and Burstein, Harold J.
- Abstract
Purpose: Metronomic chemotherapy has the potential to offer tumor control with reduced toxicity when compared to standard dose chemotherapy in patients with metastatic breast cancer. As metronomic chemotherapy may target the tumor microvasculature, it has the potential for synergistic effects with antiangiogenic agents such as the VEGF-A inhibitor bevacizumab. Methods: In this randomized phase II study, patients with metastatic breast cancer were randomized to receive metronomic oral cyclophosphamide and methotrexate (CM) combined with bevacizumab (Arm A) or CM alone (Arm B). The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety and tolerability. Results: A total of 55 patients were enrolled, with 34 patients treated on Arm A and 21 patients treated on Arm B. The ORR was modestly higher in Arm A (26%) than in Arm B (10%); neither met the 40% cutoff for further clinical evaluation. The median time to progression (TTP) was 5.52 months (3.22–13.6) on Arm A and 1.82 months (1.54–6.70) on Arm B (log-rank p = 0.008). The median OS was 29.6 months (17.2–NA) on Arm A and 16.2 months (15.7–NA) on Arm B (log-rank p = 0.7). Common all-grade adverse events in both arms included nausea, fatigue, and elevated AST. Conclusion: The combination of metronomic CM with bevacizumab significantly improved PFS over CM alone, although there was no significant difference in OS. Oral metronomic chemotherapy alone has limited activity in advanced breast cancer. ClinicalTrials.gov Identifier: NCT00083031. Date of Registration: May 17, 2004. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Taxanes for the treatment of breast cancer during pregnancy: an international cohort study.
- Author
-
Guajardo, Ana S Ferrigno, Vaca-Cartagena, Bryan F, Mayer, Erica L, Bousrih, Chayma, Oluchi, Oke, Saura, Cristina, Peccatori, Fedro, Muñoz-Montaño, Wendy, Cabrera-Garcia, Alvaro, Lambertini, Matteo, Corrales, Luis, Becerril-Gaitan, Andrea, Sella, Tal, Newman, Alexandra Bili, Pistilli, Barbara, Martinez, Ashley, Ortiz, Carolina, Joval-Ramentol, Laia, Scarfone, Giovanna, and Buonomo, Barbara
- Subjects
PREMATURE rupture of fetal membranes ,SMALL for gestational age ,BREAST cancer ,FETAL growth retardation ,TAXANES ,PREGNANCY - Abstract
Introduction The addition of taxanes to anthracycline-based chemotherapy is considered standard of care in the treatment of breast cancer. However, there are insufficient data regarding the safety of taxanes during pregnancy. The aim of this study was to describe the incidence of obstetric and neonatal adverse events associated with the use of taxane-containing chemotherapy regimens for the treatment of breast cancer during pregnancy. Methods This is a multicenter, international cohort study of breast cancer patients treated with taxanes during pregnancy. A descriptive analysis was undertaken to synthetize available data. Results A total of 103 patients were included, most of whom were treated with paclitaxel and anthracyclines given in sequence during gestation (90.1%). The median gestational age at taxane initiation was 28 weeks (range = 12-37 weeks). Grade 3-4 adverse events were reported in 7 of 103 (6.8%) patients. The most common reported obstetric complications were intrauterine growth restriction (n = 8 of 94, 8.5%) and preterm premature rupture of membranes (n = 5 of 94, 5.3%). The live birth rate was 92 of 94 (97.9%), and the median gestational age at delivery was 37 weeks (range = 32-40 weeks). Admission to an intensive care unit was reported in 14 of 88 (15.9%) neonates, and 17 of 70 (24.3%) live births resulted in small for gestational age neonates. Congenital malformations were reported in 2 of 93 (2.2%). Conclusion Obstetric and neonatal outcomes after taxane exposure during pregnancy were generally favorable and did not seem to differ from those reported in the literature with standard anthracycline-based regimens. This study supports the use of taxanes during gestation when clinically indicated. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
- Author
-
Mayer, Erica L., Tayob, Nabihah, Ren, Siyang, Savoie, Jennifer J., Spigel, David R., Burris III, Howard A., Ryan, Paula D., Harris, Lyndsay N., Winer, Eric P., and Burstein, Harold J.
- Abstract
Purpose: Metronomic chemotherapy has the potential to offer tumor control with reduced toxicity when compared to standard dose chemotherapy in patients with metastatic breast cancer. As metronomic chemotherapy may target the tumor microvasculature, it has the potential for synergistic effects with antiangiogenic agents such as the VEGF-A inhibitor bevacizumab. Methods: In this randomized phase II study, patients with metastatic breast cancer were randomized to receive metronomic oral cyclophosphamide and methotrexate (CM) combined with bevacizumab (Arm A) or CM alone (Arm B). The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety and tolerability. Results: A total of 55 patients were enrolled, with 34 patients treated on Arm A and 21 patients treated on Arm B. The ORR was modestly higher in Arm A (26%) than in Arm B (10%); neither met the 40% cutoff for further clinical evaluation. The median time to progression (TTP) was 5.52 months (3.22–13.6) on Arm A and 1.82 months (1.54–6.70) on Arm B (log-rank p = 0.008). The median OS was 29.6 months (17.2–NA) on Arm A and 16.2 months (15.7–NA) on Arm B (log-rank p = 0.7). Common all-grade adverse events in both arms included nausea, fatigue, and elevated AST. Conclusion: The combination of metronomic CM with bevacizumab significantly improved PFS over CM alone, although there was no significant difference in OS. Oral metronomic chemotherapy alone has limited activity in advanced breast cancer. ClinicalTrials.gov Identifier: NCT00083031. Date of Registration: May 17, 2004. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.
- Author
-
Kantor, Olga, King, Tari A., Jones, Alyssa, Glass, Charity, Leonard, Saskia J., Ogayo, Esther R., Mayer, Erica L., Chavez-MacGregor, Mariana, Newman, Lisa A., Freedman, Rachel A., and Mittendorf, Elizabeth A.
- Abstract
Background: Racial and ethnic disparities in outcomes after treatment for ductal carcinoma in situ (DCIS) are largely unknown. The objective of this study was to examine breast cancer outcomes by race and ethnicity in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-35 clinical trial. Patients and Methods: The NSABP B-35 trial randomized postmenopausal women with hormone receptor-positive DCIS treated with breast-conserving therapy to 5 years of tamoxifen or anastrozole. In total, 3104 women were enrolled between 2003 and 2006. For this analysis, patients without complete self-reported race and ethnicity or with immediate trial dropout were excluded. Kaplan–Meier curves and adjusted Cox-proportional hazards models were used for analyses. Results: Of the 3061 women included, 2614 (85.4%) were non-Hispanic white (NHW), 255 (8.3%) were non-Hispanic Black (NHB), 95 (3.1%) were Hispanic, and 96 (3.1%) were Asian or Pacific Islander (API). Endocrine therapy assignment and duration were well balanced between racial and ethnic groups. Median follow-up was 9 years; unadjusted Kaplan–Meier curves did not show any racial differences in disease events. Adjusted Cox-proportional hazards models found API (versus NHW) race to be associated with higher local recurrence [hazard ratio (HzR) 2.45, p = 0.035] and NHB race to be associated with higher distant recurrence (HzR 5.03, p = 0.020) and breast cancer mortality (HzR 3.83, p = 0.046). Conclusions: Despite similar locoregional treatments and standard endocrine therapy in a clinical trial population, racial and ethnic disparities exist in long-term outcomes for hormone-receptor-positive DCIS. These findings suggest that factors outside of access and treatment may impact DCIS outcomes by race and ethnicity. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I–III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical Trial.
- Author
-
Glass, Charity C., Pride, Robert M., Freedman, Rachel A., Mayer, Erica L., Ogayo, Esther R., Chavez-MacGregor, Mariana, King, Tari A., Mittendorf, Elizabeth A., and Kantor, Olga
- Abstract
Background: There are limited data examining racial disparities in locoregional recurrence (LRR) among women with access to high-quality care. We aimed to examine differences in late LRR by race in patients with stage I–IIIA, hormone receptor-positive (HR+) breast cancer enrolled in the National Surgical Adjuvant Breast and Bowel (NSABP) B-42 trial. Methods: From 2006 to 2010, 3966 postmenopausal women with stage I–IIIA HR+ breast cancer who were disease-free after 5 years of endocrine therapy were randomized to an additional 5 years of endocrine therapy or placebo. Patients were excluded if multi-racial or if race was unknown. Kaplan–Meier curves were used to estimate 6-year LRR from the time of trial registration and according to race. Cox proportional hazards models were used for adjusted survival analyses. Results: Overall, 3929 NSABP B-42 patients were included: 3688 (93.9%) White, 151 (3.8%) Black, and 90 (2.3%) Asian patients. Median follow-up was 75.2 months. Overall estimated 6-year LRR from trial registration was 1.8% and differed by race: LRR rates were 1.7% in White women, 4.9% in Black women, and 0% in Asian women (p = 0.046). Adjusted Cox proportional hazards analysis found Black race to be independently associated with LRR (hazard ratio [HzR] 2.36, 95% confidence interval [CI] 1.01–5.49; p = 0.047). Node-positivity was also associated with increased LRR (HzR 1.75, 95% CI 1.07–2.86; p = 0.025). Adjusted Cox analysis found LRR (HzR 2.32, 95% CI 1.33–4.06; p = 0.003) to be associated with increased overall mortality; however, race was not independently associated with mortality. Conclusion: Among postmenopausal patients with stage I–IIIA HR+ breast cancer in the NSABP B-42 trial, racial differences in late LRR were present, with the highest LRR in Black women. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Clonal hematopoiesis in older patients with breast cancer receiving chemotherapy.
- Author
-
Mayerhofer, Christina, Sedrak, Mina S, Hopkins, Judith O, Li, Tianyu, Tayob, Nabihah, Faggen, Meredith G, Sinclair, Natalie F, Chen, Wendy Y, Parsons, Heather A, Mayer, Erica L, Lange, Paulina B, Basta, Ameer S, Perilla-Glen, Adriana, Lederman, Ruth I, Wong, Andrew R, Tiwari, Abhay, McAllister, Sandra S, Mittendorf, Elizabeth A, Gibson, Christopher J, and Burstein, Harold J
- Subjects
HORMONE receptor positive breast cancer ,OLDER patients ,DNA repair ,CANCER chemotherapy ,SOMATIC mutation ,CANCER patients - Abstract
Background The expansion of hematopoietic stem cells carrying recurrent somatic mutations, termed clonal hematopoiesis (CH), is common in elderly individuals and is associated with increased risk of myeloid malignancy and all-cause mortality. Though chemotherapy is a known risk factor for developing CH, how myelosuppressive therapies affect the short-term dynamics of CH remains incompletely understood. Most studies have been limited by retrospective design, heterogeneous patient populations, varied techniques to identifying CH, and analysis of single timepoints. Methods We examined serial samples from 40 older women with triple-negative or hormone receptor–positive breast cancer treated on the prospective ADjuVANt Chemotherapy in the Elderly trial to evaluate the prevalence and dynamics of CH at baseline and throughout chemotherapy (6 and 12 weeks). Results CH was detected in 44% of patients at baseline and in 53% at any timepoint. Baseline patient characteristics were not associated with CH. Over the course of treatment, mutations exhibited a variety of dynamics, including emergence, expansion, contraction, and disappearance. All mutations in TP53 (n = 3) and PPM1D (n = 4), genes that regulate the DNA damage response, either became detectable or expanded over the course of treatment. Neutropenia was more common in patients with CH, particularly when the mutations became detectable during treatment, and CH was significantly associated with cyclophosphamide dose reductions and holds (P = .02). Conclusions Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies. Trial Registration ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT03858322). Clinical trial registration number: NCT03858322. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer.
- Author
-
Brett, Jamie O. and Mayer, Erica L.
- Abstract
Opinion statement: For high-risk early-stage hormone-receptor-positive, HER2-negative breast cancer (HR + /HER2 − EBC), short- and long-term recurrence risks remain substantial despite local control with surgery and radiation and systemic treatment with chemotherapy and endocrine therapy (ET). Recent trials have provided new strategies for reducing recurrence. The monarchE trial demonstrated that adding 2 years of adjuvant abemaciclib to ET improves invasive disease-free survival (iDFS) and distant recurrence-free survival (DRFS). In the OlympiA trial for high-risk disease in patients with germline BRCA1/BRCA2 mutations, adding 1 year of olaparib to ET improved iDFS, DRFS, and overall survival (OS). In addition, for premenopausal women with high-risk tumors, long-term follow-up of the SOFT, ASTRRA, TEXT, ABCSG-12, and HOBOE trials supports the role of ovarian function suppression (OFS), in combination with adjuvant tamoxifen or aromatase inhibition (AI). For postmenopausal women with high-risk tumors, extended-duration AI for at least 7 years should be used with zoledronic acid. Given the remaining recurrence risk even with these interventions and with the ongoing development of new strategies for HR + disease, patients with high-risk EBC should be encouraged to participate in clinical trials, such as trials of immunotherapy, novel oral estrogen receptor alpha (ERα)-targeting agents, antibody–drug conjugates (ADCs), and trials guided by measurements of minimal residual disease (MRD). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.
- Author
-
Haddad, Tufia C., Suman, Vera J., D'Assoro, Antonino B., Carter, Jodi M., Giridhar, Karthik V., McMenomy, Brendan P., Santo, Katelyn, Mayer, Erica L., Karuturi, Meghan S., Morikawa, Aki, Marcom, P. Kelly, Isaacs, Claudine J., Oh, Sun Young, Clark, Amy S., Mayer, Ingrid A., Keyomarsi, Khandan, Hobday, Timothy J., Peethambaram, Prema P., O'Sullivan, Ciara C., and Leon-Ferre, Roberto A.
- Published
- 2023
- Full Text
- View/download PDF
13. Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor–Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial.
- Author
-
Kantor, Olga, King, Tari A., Freedman, Rachel A., Mayer, Erica L., Chavez-MacGregor, Mariana, Korde, Larissa A., Sparano, Joseph A., and Mittendorf, Elizabeth A.
- Published
- 2023
- Full Text
- View/download PDF
14. The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer.
- Author
-
Grinshpun, Albert, Tolaney, Sara M., Burstein, Harold J., Jeselsohn, Rinath, and Mayer, Erica L.
- Published
- 2023
- Full Text
- View/download PDF
15. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment.
- Author
-
Turner, Nicholas, Huang-Bartlett, Cynthia, Kalinsky, Kevin, Cristofanilli, Massimo, Bianchini, Giampaolo, Chia, Stephen, Iwata, Hiroji, Janni, Wolfgang, Ma, Cynthia X, Mayer, Erica L, Park, Yeon Hee, Fox, Steven, Liu, Xiaochun, McClain, Sasha, and Bidard, Francois-Clement
- Abstract
ESR1 mutation (ESR1m) is a frequent cause of acquired resistance to aromatase inhibitor (AI) plus cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), which is a first-line therapy for hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). Camizestrant is a next-generation oral selective estrogen receptor degrader (SERD) that in a phase II study significantly improved progression-free survival (PFS) over fulvestrant (also a SERD) in ER+/HER2- ABC. SERENA-6 (NCT04964934) is a randomized, double-blind, phase III study evaluating the efficacy and safety of switching from an AI to camizestrant, while maintaining the same CDK4/6i, upon detection of ESR1m in circulating tumor DNA before clinical disease progression on first-line therapy for HR+/HER2- ABC. The aim is to treat ESR1m clones and extend the duration of control of ER-driven tumor growth, delaying the need for chemotherapy. The primary end point is PFS; secondary end points include chemotherapy-free survival, time to second progression event (PFS2), overall survival, patient-reported outcomes and safety. Why will we perform this study? Patients with advanced breast cancer in which the cancer cells have the receptor for the hormone estrogen and/or progesterone are typically treated with an aromatase inhibitor, a hormone therapy that decreases estrogen being made in the body, together with an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), a drug that blocks the growth of cancer cells. Although cancers usually respond to treatment initially, the cancer cells eventually change, so the drug combination no longer works. For example, mutation of the estrogen receptor (referred to as ESR1m) can stop aromatase inhibitors from working. Camizestrant is an investigational drug that blocks estrogen receptors, including mutated receptors, reducing the growth and spread of cancer. Here we describe the SERENA-6 clinical trial, which is testing camizestrant as a treatment for patients with breast cancer with ESR1m. How will we perform this research? The phase III SERENA-6 trial will use blood tests to monitor if patients with breast cancer develop ESR1m while being treated with an aromatase inhibitor and a CDK4/6 inhibitor. If ESR1m is detected, yet the disease is stable, participants will be randomly assigned to either continue with the same aromatase inhibitor or switch to camizestrant while continuing with the same CDK4/6 inhibitor. The study will assess whether switching to camizestrant prolongs the time before the cancer grows, spreads or worsens. It will also assess the length of time that participants live for versus those who continue with an aromatase inhibitor. Clinical Trial Registration:NCT04964934 (ClinicalTrials.gov) SERENA-6 (NCT04964934) is an ongoing randomized, double-blind, phase III trial of camizestrant + CDK4/6i in ESR1-mutant HR+/HER2-negative advanced breast cancer during first-line treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Mechanisms of Resistance to CDK4/6 Inhibitors in Hormone Receptor-Positive (HR +) Breast Cancer: Spotlight on Convergent CDK6 Upregulation and Immune Signaling.
- Author
-
Brett, Jamie O., Herman, Paige E., Mayer, Erica L., Bardia, Aditya, and Wander, Seth A.
- Abstract
Purpose of Review: CDK4/6 inhibition (CDK4/6i) is a key component of first-line combination treatment with endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer (HR + /HER2 − MBC). Understanding and overcoming resistance are ongoing areas of investigation. Diverse resistance mechanisms have been uncovered in cell cycle regulators and growth factor signaling components, converging on upregulation of CDK6 or on perturbation of the cell cycle downstream of CDK4/6. In this review, we discuss studies in the past few years that add new findings to this growing knowledge base. Recent Findings: Recent work has shown that CDK6 upregulation in breast cancer cells induces INK4 family members (p18
INK4C and p15INK4B ), which render CDK6 (but not CDK4) resistant to CDK4/6i. CDK6 can also form a CDK4/6i-resistant complex with p27KIP1 and (unlike CDK4) can sequester p21CIP1/WAF1 away from inhibiting CDK2 in the presence of CDK4/6i. These resistant complexes may be targetable by next-generation CDK4/6i such as proteolysis targeting chimeras (PROTACs). Separately, recent work has suggested that IFN-STAT1 signaling, especially over extended durations, may be a mediator of resistance rather than efficacy of CDK4/6i in breast cancer. This is based on descriptive analyses, and experiments are required to test this hypothesis. Summary: Recent research has revealed new mechanisms of CDK4/6i resistance in HR + MBC, including CDK6 complexes with INK4 and CIP/KIP members and, controversially, IFN-STAT1 signaling. Advances in these areas will inform the development of better CDK4/6 inhibitors and new combination regimens. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
17. What's the reality for CDK4/6 inhibitors: Clinical trials or real‐world evidence?
- Author
-
Trapani, Dario and Mayer, Erica L.
- Subjects
CYCLIN-dependent kinase inhibitors ,CLINICAL trials ,BREAST cancer ,CYCLIN-dependent kinases - Abstract
Clinical trials and real‐world evidence (RWE) present conflicting results on the benefit of cyclin‐dependent kinase 4 and 6 inhibitors for patients with advanced hormone receptor–positive and human epidermal growth factor receptor‐2 overexpressing breast cancer. How can RWE be interpreted and used to help guide clinical decisions? [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Emerging Targeted Therapies for Early Breast Cancer.
- Author
-
Schlam, Ilana, Tarantino, Paolo, Morganti, Stefania, Lynce, Filipa, Trapani, Dario, Mayer, Erica L., Garrido-Castro, Ana C., Waks, Ada, and Tolaney, Sara M.
- Subjects
THERAPEUTIC use of monoclonal antibodies ,THERAPEUTIC use of antineoplastic agents ,DRUG approval ,IMMUNE checkpoint inhibitors ,EPIDERMAL growth factor receptors ,BRCA genes ,EARLY detection of cancer ,METASTASIS ,CANCER relapse ,CELL receptors ,TREATMENT effectiveness ,TRANSFERASES ,COMBINED modality therapy ,BREAST tumors - Abstract
Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in the United States (US). Most patients are diagnosed with early-stage disease; however, there is still a need to prevent recurrences that often present as incurable metastatic disease. The treatment landscape of early-stage breast cancer is evolving rapidly. The immune checkpoint inhibitor pembrolizumab is approved in combination with neoadjuvant chemotherapy for the treatment of high-risk triple-negative breast cancer (TNBC). The cyclin-dependent kinase (CDK) 4 and 6 inhibitor abemaciclib is approved for adjuvant treatment of patients with high-risk hormone receptor (HR)-positive disease. While adjuvant olaparib has shown significant improvement in outcomes for patients with pathogenic/likely pathogenic BRCA1/2 mutations and high-risk human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and is approved in this setting. For the HER2-positive subtype, the post-neoadjuvant therapy can be tailored based on the response to neoadjuvant chemotherapy and HER2-targeted agents. In this narrative review, we summarize the most recent approvals for early-stage breast cancer as well as frequently encountered clinical challenges utilizing these medications. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis.
- Author
-
Sella, Tal, Exman, Pedro, Ren, Siyang, Freret, Taylor S., Economy, Katherine E., Chen, Wendy Y., Parsons, Heather A., Lin, Nancy U., Moy, Beverly, Tung, Nadine M., Partridge, Ann H., Tayob, Nabihah, and Mayer, Erica L.
- Abstract
Background: Guidelines support comparable treatment for women diagnosed with breast cancer during pregnancy (PrBC) and nonpregnant women with limited case-specific modifications to ensure maternal–fetal safety. Experience during pregnancy with modern agents, such as taxanes or granulocyte colony-stimulating factors (GCSF), is limited. Patients and methods: We retrospectively identified a multi-institutional cohort of PrBC between 1996 and 2020. Propensity score analyses with multiple imputation for missing variables were applied to determine the associations between chemotherapy exposures during pregnancy, with or without taxanes or GCSF, and a compound maternal–fetal outcome including spontaneous preterm birth, preterm premature rupture of membranes, chorioamnionitis, small for gestational age newborns, congenital malformation, or 5-min Apgar score < 7. Results: Among 139 PrBC pregnancies, 82 (59.0%) were exposed to chemotherapy, including 26 (31.7%) to taxane and 18 (22.0%) to GCSF. Chemotherapy use, in general, and inclusion of taxane and/or GCSF, specifically, increased over time. Pregnancies resulting in live singleton births (n = 123) and exposed to chemotherapy were as likely to reach term as those that were not (59.5% vs. 63.6%, respectively, p
unadjusted = 0.85). Among women treated with chemotherapy, propensity score-matched odds ratios (OR) for the composite maternal–fetal outcome were not significantly increased with taxane (OR 1.24, 95% CI 0.27–5.72) or GCSF (OR 2.11, 95% confidence interval (CI) 0.48–9.22) with similar effects in multiple imputation and sensitivity models. Conclusion: The judicious increased use of taxane chemotherapy and/or growth factor support during pregnancy was not associated with unfavorable short-term maternal–fetal outcomes. While these findings are reassuring, case numbers remain limited and continued surveillance of these patients and progeny is warranted. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
20. ASO Visual Abstract: Racial Disparities in Locoregional Recurrence in Postmenopausal Patients with Stage I–III, Hormone Receptor-Positive Breast Cancer Enrolled in the NSABP B-42 Clinical Trial.
- Author
-
Glass, Charity C., Pride, Robert M., Freedman, Rachel A., Mayer, Erica L., Ogayo, Esther R., Chavez-MacGregor, Mariana, King, Tari A., Mittendorf, Elizabeth A., and Kantor, Olga
- Published
- 2024
- Full Text
- View/download PDF
21. Birthweight and Chemotherapy Exposure in Women Diagnosed with Breast Cancer during Pregnancy.
- Author
-
Freret, Taylor S., Exman, Pedro, Mayer, Erica L., Little, Sarah E., and Economy, Katherine E.
- Subjects
ACADEMIC medical centers ,CANCER chemotherapy ,RETROSPECTIVE studies ,ACQUISITION of data ,REGRESSION analysis ,FISHER exact test ,PRENATAL exposure delayed effects ,SEX distribution ,TREATMENT effectiveness ,BIRTH weight ,MEDICAL records ,BREAST tumors ,SMALL for gestational age ,LONGITUDINAL method ,PREGNANCY - Abstract
Objective Breast cancer is one of the most frequently diagnosed cancers in pregnancy and is commonly treated with chemotherapy. To date, studies examining effects of chemotherapy during pregnancy on fetal growth have yielded conflicting results, and most are limited by small sample sizes or are nonspecific with respect to cytotoxic regimen or type of cancer treated. We sought to evaluate the effect of chemotherapy for breast cancer in pregnancy on birthweight and small for gestational age infants. Study Design This is a retrospective cohort study of 74 women diagnosed with pathologically confirmed breast cancer during pregnancy between 1997 and 2018 at one of three academic medical centers, who had a singleton birth with known birthweight. Forty-nine received chemotherapy and 25 did not receive chemotherapy. Linear regression modeling was used to compare birthweight (by gestational age and sex-specific z -score) by chemotherapy exposure. Subanalyses of specific chemotherapy regimen and duration of chemotherapy exposure were also performed. Placental, neonatal, and maternal outcomes were also analyzed by chemotherapy exposure. Results In the adjusted model, chemotherapy exposure was associated with lower birthweight (Δ z -score = −0.49, p = 0.03), but similar rates of small for gestational age (defined as birthweight <10th percentile for gestational age) infants (8.2 vs. 8.0%, p = 1.0; Fisher's exact test). Each additional week of chemotherapy (Δ z -score = −0.05, p = 0.03) was associated with decreased birthweight, although no association was found with specific chemotherapy regimen. Chemotherapy exposure was associated with lower median placental weight percentile by gestational age (9th vs. 75th, p < 0.05). Secondary maternal outcomes were similar between the group that did and did not receive chemotherapy. Conclusion Chemotherapy for breast cancer in pregnancy in this cohort is associated with lower birthweight but no difference in the rate of small for gestational age infants. Key Points Chemotherapy for breast cancer in pregnancy is associated with decreased birthweight but similar rates of small for gestational age infants. Birthweight did not differ according to chemotherapy regimen. There is no difference in the rate of small for gestational age infants. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. The effects of a clinic‐based weight loss program on health‐related quality of life and weight maintenance in cancer survivors: A randomized controlled trial.
- Author
-
Brown, Justin C., Giobbie‐Hurder, Anita, Yung, Rachel L., Mayer, Erica L., Tolaney, Sara M., Partridge, Ann H., and Ligibel, Jennifer A.
- Subjects
WEIGHT loss ,QUALITY of life ,RANDOMIZED controlled trials ,CANCER survivors ,WORRY ,BODY weight ,SLEEP interruptions - Abstract
Objective: The Healthy Living and Eating After Cancer Trial demonstrated that a clinic‐based weight loss program reduced body weight, as compared with a waitlist control group, over 15 weeks. Here we report the impact of the weight loss intervention on health‐related quality‐of‐life outcomes at week 15, and maintenance of weight loss to week 30. Methods: This trial randomized cancer survivors of solid tumors and hematologic malignancies (breast cancer: 76.7%) to a 15‐week group‐based weight loss program (n = 30) or a waitlist control group (n = 30). Participants were not blinded to group assignment. Participants completed a variety of health‐related quality‐of‐life outcome measures at baseline and week 15. From week 15 to week 30, participants initially randomized to the weight loss program were followed with no additional intervention, and participants initially randomized to the waitlist control group commenced the weight loss program. Results: Over the 15 weeks, the weight loss program improved physical functioning (6.2 ± 2.9; p = 0.02; d = 0.31) and reduced insomnia symptoms (−17.1 ± 7.4; p = 0.03; d = −0.30) as measured by the EORTC QLQ‐C30, and sleep disturbance (−4.9 ± 1.6; p = 0.005; d = −0.40) as measured by PROMIS, compared to waitlist control. After a weight loss of 4.6 ± 3.9 kg, from week 15 to week 30, participants who were initially randomized to the weight loss program maintained their prior weight loss (+0.6 ± 3.5 kg) and participants who were initially randomized to the waitlist control group lost weight (−3.4 ± 2.9 kg; p < 0.001). Conclusions: In cancer survivors with overweight or obesity, a 15‐week clinic‐based weight loss program improved health‐related quality‐of‐life outcomes and produced sustained weight loss to week 30. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. Do you mind if I record?: Perceptions and practice regarding patient requests to record clinic visits in oncology.
- Author
-
Jimenez, Rachel B., Johnson, Andrew E., Horick, Nora K., Hlubocky, Fay J., Lei, Yvonne, Matsen, Cindy B., Mayer, Erica L., Collyar, Deborah E., LeBlanc, Thomas W., Donelan, Karen, Mello, Michelle M., and Peppercorn, Jeffrey M.
- Subjects
ONCOLOGISTS ,PHYSICIAN-patient relations ,LEGAL liability ,CIVIL liability ,THERAPEUTICS ,ONCOLOGY - Abstract
Background: Audio recordings of oncology clinic discussions can help patients retain and understand information about their disease and treatment decisions. Access to this tool relies on acceptance of recordings by oncologists. This is the first study to evaluate experience and attitudes of oncologists toward patients recording clinic visits. Methods: Medical, radiation, and surgical oncologists from 5 US cancer centers and community affiliates were surveyed to evaluate clinicians' experience, beliefs, and practices regarding patient‐initiated recordings. Results: Among 360 oncologists (69% response rate), virtually all (93%) have experienced patients seeking to record visits. Although 75% are comfortable with recording, 25% are uncomfortable and 56% report concerns ranging from less thorough discussions to legal liability. Most (85%) always agree when patients ask to record, but 15% never or selectively allow recording. Although 51% believe recording is positive for the patient‐physician relationship, a sizable minority report that it can lead to less detailed conversations (28%) or avoidance of difficult topics, including prognosis (33%). Views did not vary based on subspecialty, practice setting, or geographic region, but older age and years in practice were associated with more positive views of recording. The majority of clinicians (72%) desire institutional policies to govern guidelines about recordings. Conclusions: Most oncologists are comfortable with patient requests to record visits, but a sizable minority remain uncomfortable, and access to recording varies solely on physician preference. This difference in care delivery may benefit from institutional policies that promote access while addressing legitimate physician concerns over privacy and appropriate use of recordings. Most oncologists are comfortable with patients recording consultations; however, 25% are uncomfortable, and more than half (56%) express concerns related to legal liability and limiting transparent discussions with patients. Institutional policies are needed to address the concerns of oncologists and enhance equitable care for patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Dana-Farber Cancer Institute/Mass General Brigham Fellowship Response to the COVID-19 Pandemic.
- Author
-
Stern, Robert M., Michaelson, M. Dror, Mayer, Erica L., Parnes, Aric D., Fogerty, Annemarie E., LaCasce, Ann S., and Nipp, Ryan D.
- Subjects
WELL-being ,COVID-19 ,SCHOLARSHIPS ,COMMUNICATION ,STUDENT attitudes ,SOCIAL distancing ,TECHNOLOGY ,COVID-19 pandemic ,TELEMEDICINE - Abstract
The coronavirus disease (COVID)-19 pandemic has affected graduate medical education training programs, including hematology-oncology fellowship programs, both across the United States and abroad. Within the Dana-Farber Cancer Institute/Mass General Brigham hematology-oncology fellowship program, fellowship leadership had to quickly reorganize the program's clinical, educational, and research structure to minimize the risk of COVID-19 spread to our patients and staff, allow fellows to assist in the care of patients with COVID-19, maintain formal didactics despite physical distancing, and ensure the mental and physical well-being of fellows. Following the first wave of patients with COVID-19, we anonymously surveyed the Dana-Farber Cancer Institute/Mass General Brigham first-year fellows to explore their perceptions regarding what the program did well and what could have been improved in the COVID-19 response. In this article, we present the feedback from our fellows and the lessons we learned as a program from this feedback. To our knowledge, this represents the first effort in the hematology-oncology literature to directly assess a hematology-oncology program's overall response to COVID-19 through direct feedback from fellows. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.
- Author
-
Lynce, Filipa, Williams, James T., Regan, Meredith M., Bunnell, Craig A., Freedman, Rachel A., Tolaney, Sara M., Chen, Wendy Y., Mayer, Erica L., Partridge, Ann H., Winer, Eric P., and Overmoyer, Beth
- Subjects
PACLITAXEL ,METASTATIC breast cancer ,TRIPLE-negative breast cancer - Abstract
Purpose: Preclinical studies support the JAK2–STAT3 signaling pathway as a key driver in CD44+ CD24− "stem-cell-like" breast cancer cells. Ruxolitinib is an orally bioavailable JAK1/2 inhibitor. We aimed to identify the recommended phase 2 dose (RP2D) of ruxolitinib in combination with paclitaxel in patients with HER2-negative metastatic breast cancer (MBC). Methods: Eligible patients had HER2-negative MBC and had received ≤ 3 chemotherapy regimens for advanced disease. Patients received oral ruxolitinib (10–25 mg bid) in a 3 + 3 dose escalation design in combination with weekly paclitaxel 80 mg/m
2 in a 3-week cycle. The primary objective was to determine the maximum tolerated dose (MTD) and the RP2D. Results: Nineteen patients received protocol therapy (mean age 52 years). Eight (42%) had triple-negative breast cancer and 11 (58%) had hormone receptor-positive disease; 12 (63%) had visceral disease. Ten (53%) patients had not received prior treatment for advanced disease. Patients received a median number of 5 cycles of combination therapy (range 1–12) and five patients continued single-agent ruxolitinib. The MTD of ruxolitinib was 25 mg bid when combined with paclitaxel, and the RP2D for the combination was 15 mg bid. Thirteen (68%) patients required dose reductions or holds. Most frequent toxicities reported of any grade were neutropenia (50%) and anemia (33%). There were no grade 4/5 toxicities attributed to study drug. Four (21%) patients had PR, 12 (63%) had SD and three (16%) had PD as their best response. Conclusion: The combination of ruxolitinib and weekly paclitaxel was well tolerated with evidence of clinical activity. Further analysis of this combination is ongoing (NCT02041429). Trial registration: NCT02041429. Date of registration: January 22, 2014. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
26. A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.
- Author
-
Filho, Otto Metzger, Giobbie-Hurder, Anita, Lin, Nancy U., Faggen, Meredith, Come, Steven, Openshaw, Thomas, Constantine, Michael, Walsh, Jeanna, Freedman, Rachel A., Schneider, Bryan, Burstein, Harold J., and Mayer, Erica L.
- Abstract
Purpose: Adverse events (AE) during oncology clinical trials are typically reported using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), which provides information about the frequency and severity of AEs from the provider's perspective. Instruments that track patient-reported outcomes (PRO) complement the CTCAE and provide additional patient-centered information about the toxicity profile of an anti-cancer drug. Methods: We conducted a single-arm, open-label phase II study of eribulin as first- or second-line therapy for metastatic hormone receptor-positive/HER2-negative (HR+/HER2−) or triple-negative breast cancer (TNBC). Patients were recruited simultaneously into each cohort by tumor subtype. The primary endpoint was overall response rate (ORR). Secondary endpoints included evaluation of toxicity by CTCAE and PRO instruments and agreement between CTCAE and PRO. The study also investigated single-nucleotide polymorphisms (SNPs) associated with treatment-induced neurotoxicity. Results: 83 patients were enrolled: 45 into the HR+/HER2− cohort and 38 into the TNBC cohort. The ORR was 35.6% (90% CI 24–39%) in the HR+/HER2− cohort and 13.2% (90% CI 5–26%) in the TNBC cohort. Stable disease as the best response was recorded in 55.1% of patients with HR+/HER2− disease and 60.5% with TNBC. Toxicity analysis revealed a discordance between CTCAE and PRO assessment in many patients, with a focus on fatigue, alopecia, and neuropathy. Pharmacogenomic analysis identified SNPs associated with treatment-induced peripheral neuropathy. Conclusions: Eribulin is active in HER2− breast cancer. This study reveals that provider-assessed AEs can vary greatly from patient experiences. Future studies should incorporate CTCAE and PRO instruments to improve reporting of treatment-related AEs. ClinicalTrials.gov Registration: NCT01827787 [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.
- Author
-
Goel, Shorn, Pernas, Sonia, Zhenying Tan-Wasielewski, Barry, William T., Bardia, Aditya, Rees, Rebecca, Andrews, Chelsea, Tahara, Rie Kawabori, Trippa, Lorenzo, Mayer, Erica L., Winer, Eric P., Spring, Laura M., Tolaney, Sara M., Goel, Shom, and Tan-Wasielewski, Zhenying
- Published
- 2019
- Full Text
- View/download PDF
28. Contemporary management of breast cancer during pregnancy and subsequent lactation in a multicenter cohort of young women with breast cancer.
- Author
-
Lee, Guek Eng, Rosenberg, Shoshana M, Mayer, Erica L, Borges, Virginia, Meyer, Meghan E, Schapira, Lidia, Come, Steven E, and Partridge, Ann H
- Subjects
BREAST tumor diagnosis ,BREAST tumor treatment ,ABORTION ,BREASTFEEDING ,CANCER invasiveness ,CELL receptors ,CHILDBIRTH ,COMBINED modality therapy ,DELIVERY (Obstetrics) ,GESTATIONAL age ,LACTATION ,LONGITUDINAL method ,MEDICAL cooperation ,MEDICAL records ,ONCOGENES ,FIRST trimester of pregnancy ,SECOND trimester of pregnancy ,THIRD trimester of pregnancy ,RESEARCH ,SURVEYS ,WOMEN'S health ,LUMPECTOMY ,TREATMENT effectiveness ,ACQUISITION of data methodology ,PREGNANCY - Abstract
The incidence of breast cancer diagnosed during pregnancy is increasing. We sought to characterize patient, treatment, pregnancy and lactation factors among young women with newly diagnosed breast cancer during pregnancy in a prospective cohort study. We identified all women who were pregnant when diagnosed with invasive breast cancer among those enrolled in the Young Women's Breast Cancer Study (NCT01468246), and collected details on pregnancy, birth and lactation from surveys, and treatment information medical record review. Of 1302 enrolled participants, 976 women with invasive breast cancer completed full baseline surveys, among whom 39 (4.0%) patients reported being pregnant at diagnosis. Median age at diagnosis was 34 years (range: 25‐40), with stage distribution: I, 28%; II, 44%; III, 23%; and IV, 5%. 74% of patients (29/39) had grade 3 tumors, 59% (23/39) ER‐positive, and 31% (12/39) HER2‐positive disease. 23 (59%) had surgery during pregnancy, 4 (17%) during the first trimester. Among the women who had surgery during pregnancy, 61% (14/23) underwent lumpectomy, 35% (8/23) unilateral, and 4% (1/23) bilateral mastectomy. All patients who had chemotherapy (51%, 20/39) received it in second and third trimesters, and had ACx4. There were 31 live births, 2 spontaneous, and 5 therapeutic abortions. Among live births, 16 (41%) were before 37 weeks of gestation. Three women reported breastfeeding. Within 6 months after delivery, comprehensive staging in 13 patients showed upstaging in four patients. In a contemporary cohort of young women with breast cancer, pregnancy at diagnosis is relatively uncommon. Treatment during pregnancy can generally be consistent with standard surgical and chemotherapy approaches, with attention to timing of therapies. Longer‐term outcomes including effects of some timing issues including delayed use of anti‐HER2 therapy on patient outcomes warrant further research. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
29. Randomized trial of a clinic-based weight loss intervention in cancer survivors.
- Author
-
Brown, Justin C., Yung, Rachel L., Gobbie-Hurder, Anita, Shockro, Laura, O’Connor, Keelin, Campbell, Nancy, Kasper, Jocelyn, Mayer, Erica L., Tolaney, Sara M., Partridge, Ann H., Ligibel, Jennifer A., and O'Connor, Keelin
- Abstract
Background: This trial examined the efficacy of a clinic-based weight loss intervention in cancer survivors.Methods: This single-center phase II trial randomized survivors of solid tumors and hematologic malignancies to a 15-week group-based weight loss intervention that included caloric restriction and physical activity (n = 30) or a wait-list control intervention (n = 30). The primary study outcome was body mass. Secondary study outcomes included body composition using dual-energy X-ray absorptiometry, physical fitness using the 6-min walk test (6MWT), and concentrations of serum biomarkers.Results: Participants in the intervention group lost 5.6 ± 4.4% of baseline weight (4.6 ± 3.9 kg), whereas participants in the control group gained 0.2 ± 2.4% of baseline weight (0.2 ± 2.0 kg); intervention effect - 5.8% (95% CI - 7.8, - 3.8); - 4.8 kg (95% CI - 6.6, - 3.0); P = 0.0001. A larger proportion of participants in the intervention group lost ≥ 5% of baseline weight compared to the control group (43 vs 0%; P < 0.0001). The intervention led to reductions in fat mass (- 3.2 ± 0.7 kg; P < 0.0001), improvements in physical fitness (an increase of 22.6 ± 10.8 m on 6MWT; P = 0.03), and reductions in concentrations of insulin (- 7.7 ± 3.5 μU/mL; P = 0.004) and leptin (- 7.3 ± 4.0 ng/mL; P = 0.04).Conclusion: A 15-week clinic-based weight loss intervention resulted in significant weight loss and improvements in body composition, physical fitness, and concentrations of serum biomarkers in cancer survivors.Implications For Cancer Survivors: Weight loss programs provide a number of benefits for cancer survivors; survivors should inquire about the availability of lifestyle programs offered at their cancer center and within their local communities. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
30. Staging Workup in Pregnant Cancer Patients.
- Author
-
O'Neill, Ailbhe C., DiPiro, Pamela J., and Mayer, Erica L.
- Published
- 2016
- Full Text
- View/download PDF
31. Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors.
- Author
-
Irwin, Melinda L., Cartmel, Brenda, Harrigan, Maura, Li, Fangyong, Sanft, Tara, Shockro, Laura, O'Connor, Keelin, Campbell, Nancy, Tolaney, Sara M., Mayer, Erica L., Yung, Rachel, Freedman, Rachel A., Partridge, Ann H., and Ligibel, Jennifer A.
- Subjects
HEALTH of cancer patients ,PHYSICAL activity ,EXERCISE ,CANCER prevention ,QUALITY of life ,TUMOR diagnosis ,TUMOR treatment ,BODY composition ,COMPARATIVE studies ,FATIGUE (Physiology) ,RESEARCH methodology ,MEDICAL cooperation ,HEALTH outcome assessment ,PHYSICAL fitness ,PUBLIC health surveillance ,RESEARCH ,RESEARCH funding ,SELF-evaluation ,TUMORS ,EVALUATION research ,CASE-control method - Abstract
Background: Physical activity (PA) has been linked to a lower risk of developing and dying of cancer, yet many cancer survivors do not exercise. In the current study, the authors evaluated the impact of the LIVESTRONG at the YMCA exercise program, available at Young Men's Christian Associations (YMCAs) across the United States, on PA, fitness, quality of life, fatigue, body composition, serum biomarkers, and program safety in cancer survivors.Methods: Cancer survivors were recruited through the Yale Cancer Center and the Dana-Farber Cancer Institute and randomized to a 12-week, twice-weekly LIVESTRONG at the YMCA exercise program at YMCAs in Connecticut or Massachusetts or to a control group. Questionnaires, dual-energy x-ray absorptiometry scans, 6-minute walk tests (6MWTs), and a fasting blood draw were completed at baseline and at 12 weeks. Intervention effects were evaluated using mixed model repeated measures analysis, with changes at 12 weeks in PA and 6MWT as the primary endpoints.Results: A total of 186 participants were randomized (95 to the exercise group and 91 to the control group). The majority of patients were diagnosed with AJCC stage I to II cancer and 53% had breast cancer. Participants randomized to the LIVESTRONG at the YMCA program experienced increases in PA (71% exercising at ≥ 150 minutes/week vs 26% of controls; P<.05) and improvements in the 6MWT (group difference: 28.9 meters [95% confidence interval, 0.3-49.0; P = .004]) and quality of life (group difference: 2.6 [95% confidence interval, 0.1-5.0; P = .04]). No adverse events were reported.Conclusions: The LIVESTRONG at the YMCA exercise program has the potential to impact thousands of survivors across the YMCA network and could lead to improvements in disease and psychosocial outcomes in the growing population of cancer survivors. Cancer 2017;123:1249-1258. © 2016 American Cancer Society. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
32. Tamoxifen Directly Inhibits Platelet Angiogenic Potential and Platelet-Mediated Metastasis.
- Author
-
Johnson, Kelly E., Forward, Jodi A., Tippy, Mason D., Ceglowski, Julia R., El-Husayni, Saleh, Kulenthirarajan, Rajesh, Machlus, Kellie R., Mayer, Erica L., Italiano Jr, Joseph E., and Battinelli, Elisabeth M.
- Published
- 2017
- Full Text
- View/download PDF
33. Immediate breast reconstruction following mastectomy in pregnant women with breast cancer.
- Author
-
Caragacianu, Diana L., Mayer, Erica L., Chun, Yoon S., Caterson, Stephanie, Bellon, Jennifer R., Wong, Julia S., Troyan, Susan, Rhei, Esther, Dominici, Laura S., Economy, Katherine E., Tung, Nadine M., Schapira, Lidia, Partridge, Ann, and Calvillo, Katherina Zabicki
- Published
- 2016
- Full Text
- View/download PDF
34. Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment.
- Author
-
Truong, Sandy R., Barry, William T., Moslehi, Javid J., Baker, Emily L., Mayer, Erica L., and Partridge, Ann H.
- Subjects
ANTHRACYCLINES ,BREAST tumors ,CANCER treatment ,CARDIOTOXICITY ,ECHOCARDIOGRAPHY ,CARDIAC radionuclide imaging ,LONGITUDINAL method ,MEDICAL screening ,RESEARCH funding ,TRASTUZUMAB ,SPECIALTY hospitals ,PRE-tests & post-tests ,RETROSPECTIVE studies - Abstract
Background. Cardiotoxicity can be a complication of anthracycline- or trastuzumab-based therapy for breast cancer patients. Screening echocardiograms (ECHOs) and radionuclide ventriculograms (RVGs) are often performed before administration of these agents to evaluate cardiac function. Limited evidence for the clinical utility of these screening tests is available. Methods. Early-stage breast cancer patients diagnosed from 2006 to 2011 (n < 1,067) with baseline ECHOs/RVGs were identified in a single institution prospective registry. Medical record review was performed to obtain pre- and post-ECHO/ RVG treatment plans, baseline ECHO/RVG results, cardiac risk factors, and cardiac events. Patients with cardiac history were excluded. ECHO/RVG abnormalities were defined as ejection fraction (EF) <55%, valvular disease, left ventricular hypertrophy, and diastolic dysfunction. Cardiac events were defined as heart failure, myocardial infarction, arrhythmia, valvular disease, or angina during or after chemotherapy. Results. Among 600 eligible patients, abnormal ECHO/RVG results were observed in 13 (2.2%, 1.2%-3.7%), including 9 with baseline EF <55%. There were no detected changes in treatment plans, although more frequent cardiac monitoring was recommended for 2 patients. There were no significant differences in age, race, menopausal status, smoking history, alcohol use, body mass index, or medical comorbidities between patients with abnormal and normal results. In follow-up (mean, 4.0 years; range, 0-8.3), 15 patients developed cardiac events (none of whom had had abnormal baseline ECHOs/RVGs). Conclusion. Baseline ECHO/RVG in patients without prior cardiac history rarely yields an abnormality that prompts change in planned anthracycline- and/or trastuzumab-based treatment. Moreover, few cardiac events developed in this screened population in follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
35. Targeting Breast Cancer with CDK Inhibitors.
- Author
-
Mayer, Erica L.
- Abstract
Dysregulation of the cell cycle is a classic hallmark of cancer growth and metastatic potential. Re-establishing cell cycle control through CDK inhibition has emerged as an attractive option in the development of targeted cancer therapy. Three oral agents selectively targeting CDK4/6 have been developed: palbociclib, abemaciclib, and LEE011. Preclinical models show optimal activity in hormone receptor positive breast cancer, which may display biologic features suggesting particular dependence on the CDK4/cyclin D1/ Rb interaction. Palbociclib has been studied in a randomized phase 2 clinical trial in metastatic hormone receptor positive breast cancer in which the combination of palbociclib and endocrine therapy significantly prolonged progression-free survival over endocrine therapy alone. The toxicity profile of palbociclib and the other CDK 4/6 inhibitors in early phase I and II trials has been predominantly hematologic, characterized by limited neutropenia, as well as variable gastrointestinal toxicity. Multiple phase II and III studies are ongoing with all three agents, and are designed to explore the role of CDK 4/6 inhibition in metastatic hormone receptor positive breast cancer. The next wave of studies will examine further clinical and scientific topics, including the role of CDK 4/6 inhibition in the neo/adjuvant setting, the combination of CDK 4/6 inhibitors with other targeted therapies, and the activity of CDK 4/6 inhibitors in the HER2 positive subset of breast cancer, as well as in other cancer subtypes. Should ongoing study confirm benefits and tolerability of CDK 4/6 inhibition, combination therapy with endocrine agents may become a new standard of care for hormone receptor positive breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
36. Long-Term Follow-Up After Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer.
- Author
-
Mayer, Erica L., Gropper, Adrienne B., Harris, Lyndsay, Gold, Julie M., Parker, Leroy, Kuter, Irene, Come, Steven, Najita, Julie S., Hao Guo, Winer, Eric P., and Burstein, Harold J.
- Published
- 2015
- Full Text
- View/download PDF
37. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
- Author
-
Lin, Nancy U., Freedman, Rachel A., Ramakrishna, Naren, Younger, Jerry, Storniolo, Anna Maria, Bellon, Jennifer R., Come, Steven E., Gelman, Rebecca S., Harris, Gordon J., Henderson, Mark A., MacDonald, Shannon M., Mahadevan, Anand, Eisenberg, Emily, Ligibel, Jennifer A., Mayer, Erica L., Moy, Beverly, Eichler, April F., and Winer, Eric P.
- Abstract
Brain metastases are common in patients with advanced, Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer. We evaluated the maximum tolerated dose (MTD) and feasibility of lapatinib given concurrently with whole brain radiotherapy (WBRT). Eligible patients had (HER2)-positive breast cancer and ≥1 brain metastasis. Patients received lapatinib 750 mg twice on day one followed by 1000, 1250, or 1500 mg once daily. WBRT (37.5 Gy, 15 fractions) began 1–8 days after starting lapatinib. Lapatinib was continued through WBRT. Following WBRT, patients received trastuzumab 2 mg/kg weekly and lapatinib 1000 mg once daily. The regimen would be considered feasible if <3/27 pts treated at the MTD experienced a dose-limiting toxicity (DLT). Thirty-five patients were enrolled; 17 % had central nervous disease (CNS) only. During dose escalation, no patients receiving 1,000 or 1,250 mg and two of five patients receiving 1,500 mg experienced DLTs (grade 3 mucositis and rash). Overall, 7/27 patients at 1,250 mg (MTD) had DLTs: grade 3 rash ( n = 2), diarrhea ( n = 2), hypoxia ( n = 1), and grade 4 pulmonary embolus ( n = 2). Among 28 evaluable patients, the CNS objective response rate (ORR) was 79 % [95% confidence interval (CI) 59–92 %] by pre-specified volumetric criteria; 46 % remained progression-free (CNS or non-CNS) at 6 months. The study did not meet the pre-defined criteria for feasibility because of toxicity, although the relationship between study treatment and some DLTs was uncertain. Given the high ORR, concurrent lapatinib-WBRT could still be considered for future study with careful safety monitoring. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
38. Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans.
- Author
-
Mayer, Erica L., Dallabrida, Susan M., Rupnick, Maria A., Redline, Whitney M., Hannagan, Keri, Ismail, Nesreen S., Burstein, Harold J., and Beckman, Joshua A.
- Published
- 2011
- Full Text
- View/download PDF
39. Inhibition of Cyclin-Dependent Kinases 4 and 6 in Breast Cancer.
- Author
-
Mayer, Erica L.
- Published
- 2015
40. Absence of blood formation in mice lacking the T-cell leukaemia oncorprotein tal-1/SCL.
- Author
-
Shivdasani, Ramesh A. and Mayer, Erica L.
- Subjects
T cells ,HEMATOPOIESIS - Abstract
Examines the role of T-cell leukaemia oncoprotein tal-1/SCL in blood formation. Characteristics of mice lacking T-cell leukaemias; Experimental procedures; Use of reverse transcriptase-polymerase chain reaction (RT-PCR).
- Published
- 1995
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.